Researchers reveal discovery of new cancer drug fadraciclib

by Institute of Cancer Research   Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research, London, in collaboration with the company Cyclacel. It is already being tested in early clinical trials targeting select hematological malignancies and solid tumors. In a new publication in the journal PLOS One, a team of scientists from Cyclacel and the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) describe the discovery of fadraciclib, formerly known as CYC065, and describe its mechanism of action and therapeutic properties. Fadraciclib is a leading dual inhibitor of two cancer-driving proteins from the cyclin-dependent kinase (CDK) family, CDK2 and CDK9.   CDK2/9 inhibitor It was designed by improving the chemical ...

• Source: drugdu
• 268
• November 1, 2020